Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DX2H9P
|
|||
| Drug Name |
Pegzilarginase
|
|||
| Drug Type |
Enzyme replacement
|
|||
| Indication | Arginase 1 deficiency [ICD-11: 5C50.A2] | Phase 3 | [1] | |
| Company |
Aeglea Biotherapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Arginase-1 (ARG1) | Target Info | Replacement | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03921541) Efficacy and Safety of Pegzilarginase in Patients With Arginase 1 Deficiency. U.S. National Institutes of Health. | |||
| REF 2 | Preclinical safety and antitumor activity of the arginine-degrading therapeutic enzyme pegzilarginase, a PEGylated, cobalt-substituted recombinant human arginase 1. Transl Res. 2020 Mar;217:11-22. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.